Polycystic Ovary Syndrome: What Derm-Associated Condition?

For the answer, click here.

Question 2:

NEXT QUESTION »

For the answer, click here.

Question 3:

NEXT QUESTION »

For the answer, click here.

Question 4:

NEXT QUESTION »

For the answer, click here.

Question 5:

ANSWER KEY »

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

ANSWER KEY:

Question 1. B

Question 2. D

Question 3. B

Question 4. B

Question 5. B

Related Content

Patient Care Staff

January 17th 2025

Distress Signals: How to Help a Clinician Colleague in Need

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

February 14th 2023

Novel Tool Predicts Onset Age of Cognitive Impairment and Alzheimer Dementia

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Rebekah Bernard, MD, a family physician and national speaker on physician wellness.

January 16th 2025

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

The Florey Dementia Index showed robustness across different cohorts but more testing is needed, researchers reported.

September 29th 2022

Annual Incidence of Dementia in US Will Double by 2060, Reaching 1 Million Cases

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.

Grace Halsey

January 15th 2025

Minimal Distress Reported with Multi-Cancer Early Detection Testing: New Findings from PATHFINDER Trial

Annual incidence of dementia will double in White adults and triple among Black adults. The updated estimates place the lifetime risk of developing dementia after age 55 at 42%.

January 14th 2025

Obstructive Sleep Apnea and Hypertension Update: FDA Clears Phase 2 Trial of Lorundrostat, an Oral Aldosterone Synthase Inhibitor

A new analysis of patient reported outcomes from the PATHFINDER study indicate the potential clinical benefit of early cancer detection.

Related Content

Patient Care Staff

January 17th 2025

Distress Signals: How to Help a Clinician Colleague in Need

Mineralys Therapeutics also expects topline data from its phase 2 study of lorundrostat for the treatment of uncontrolled hypertension or resistant hypertension when used as an add-on therapy.

February 14th 2023

Novel Tool Predicts Onset Age of Cognitive Impairment and Alzheimer Dementia

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Rebekah Bernard, MD, a family physician and national speaker on physician wellness.

January 16th 2025

Primary Viewpoints Episode 19: Mobile Health Technology for Chronic Pain Management

The Florey Dementia Index showed robustness across different cohorts but more testing is needed, researchers reported.

September 29th 2022

Annual Incidence of Dementia in US Will Double by 2060, Reaching 1 Million Cases

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Lynn Webster, MD, past president of the American Academy of Pain Medicine.

Grace Halsey

January 15th 2025

Minimal Distress Reported with Multi-Cancer Early Detection Testing: New Findings from PATHFINDER Trial

Annual incidence of dementia will double in White adults and triple among Black adults. The updated estimates place the lifetime risk of developing dementia after age 55 at 42%.

January 14th 2025